Merrimack Pharmaceuticals Profile

USD 0.07  0.64%

Acquisition by Jean Franchi of 45000 shares of Merrimack Pharmaceuticals subject to Rule 16b-3

Merrimack Pharmaceuticals Inc insider trading alert for grant of stock option (right to buy) by Jean Franchi, Chief Financial Officer, on February 18, 2018. This event was filed by Merrimack Pharmaceuticals with SEC on 2018-02-16. Statement of changes in beneficial ownership - SEC Form 4. Jean Franchi is currently serves as cfo,principal financial officer, principal accounting officer, treasurer of Merrimack Pharmaceuticals [view details]   

Merrimack Pharmaceuticals Summary

Merrimack Pharmaceuticals Inc (MACK) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 294 people. Merrimack Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 144.33 M. Merrimack Pharmaceuticals Inc conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 13.34 M outstanding shares of which 1.99 M shares are now shorted by private and institutional investors with about 11.38 trading days to cover. Merrimack Pharmac currently holds about 107.25 M in cash with (152.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.04.
Check Merrimack Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares1.6 M16.4 M
Blackrock IncCommon Shares813 K8.3 M
View Merrimack Pharmaceuticals Diagnostics

Selected Merrimack Pharmaceuticals Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Merrimack Pharmaceuticals Against Markets

Current Ratings

Merrimack Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
< 92% 
Equity ratings for Merrimack Pharmaceuticals Inc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Merrimack Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets exchange. It employs 294 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameMerrimack Pharmaceuticals Inc
CEORobert MulroyAll Leadership
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
Business AddressOne Kendall Square
Foreign Associate  India
ExchangeNASDAQ General Markets
CIK Number01274792.0
IndustryPharmaceutical Products
Contact Number617 441 1000
CurrencyUSD - US Dollar

Did you try this?

Run Aroon Oscillator Now

Aroon Oscillator

Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Hide  View All  NextLaunch Aroon Oscillator


Merrimack Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
Merrimack Pharmaceuticals Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Merrimack Pharmaceuticals Analyst Advice  


Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  


Merrimack Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.22March 1, 2017
Merrimack Pharmaceuticals Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Merrimack Pharmaceuticals Corporate Directors
George Demetri Director
Vivian Lee Director, MBA
James Quigley Director, Ph.D